跳至主要内容
临床试验/NCT04918407
NCT04918407已完成不适用

Effects of Empagliflozin in Reducing Oxidative Stress of Diabetic Recipients After Kidney Transplantation

Shahid Beheshti University of Medical Sciences2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2022年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
2
主要终点
serum level of superoxide dismutase

研究概览

简要总结

The purpose of this study is to investigate the effect of empagliflozin on oxidative stress in patients with type 2 diabetes after kidney transplantation. The association is examined by comparing the difference in oxidative modifications before and after 90 days treatment with 25 mg empagliflozin plus insulin compared to insulin treatment. The study is randomised and double-blinded. Each treatment group consists of 20 patients. Oxidative stress markers are measured by serum level of superoxide dismutase activity ,lipid peroxidation assay kit, glutathione assay, glutathione peroxidase activity , total antioxidant capacity assay oxidant status , carbonyl content assay and bca protein assay . . A student t-test will be performed to compare adding empagliflozin . The results will be published in a peer-review journal.

详细描述

With the purpose of studying the antioxidant activity of empagloflozin 25mg will add on insulin in 20 patients after kidney transplant and will compare with 20 diabetic recipient of kidney transplant on insulin therapy alone.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with type 2 diabetes
  • HbA1c: 6.5-9.0%
  • post kidney transplant
  • stable graft function

排除标准

  • pancreas and kidney transplant
  • history of recurrent urinary tract infection

研究组 & 干预措施

Empagliflozin

Experimental

Adding 25mg Empagliflozin on Insulin

干预措施: Empagliflozin 25 MG (Drug)

Empagliflozin

Experimental

Adding 25mg Empagliflozin on Insulin

干预措施: Insulin (Drug)

Insulin alone

Active Comparator

Just contriling the blood glucose with Insulin

干预措施: Insulin (Drug)

结局指标

主要结局

serum level of superoxide dismutase

时间窗: Change from baseline after 90 days of intervention

Serum level of antioxidant levels

次要结局

  • Plasma levels of malondialdehyde(Change from baseline after 90 days of intervention)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

nooshin dalili

Assistant Professor of SBMU

Shahid Beheshti University of Medical Sciences

研究点 (2)

Loading locations...

相似试验